ImmunoID NeXT Platform®
Comprehensive Genomic Profiling for Therapy Selection & Biomarker Discovery
CommercialActive
Key Facts
Indication
Comprehensive Genomic Profiling for Therapy Selection & Biomarker Discovery
Phase
Commercial
Status
Active
Company
About Personalis
Personalis is transforming cancer management through its advanced genomic sequencing and analysis technologies. The company's core offerings include the NeXT Platform® for comprehensive tumor profiling and the NeXT Personal® assay for highly sensitive MRD detection. Personalis collaborates with leading pharmaceutical companies and research institutions to accelerate drug development and improve patient outcomes. As a publicly traded company, it operates at the intersection of diagnostics, data, and therapeutic development in precision oncology.
View full company profile